This letter is a reply to a rather critical one from Bonnema. It doesn't have a doi number so I've put it here in full. My only gripe is that they insist on " normal" TSH as being proof of proper dosing. However they don't damn the use of NDT(DTE). One can take heart from that.
Dear Editor,
We thank Bonnema et al 1 for giving us the opportunity to provide further details on our recent publication 2 while addressing their insightful questions.
1. In reference to the consequences of long-term treatment with LT3, we respectfully point out that there is now solid data that LT3 does not increase the frequency of adverse reactions if serum TSH levels are maintained within the normal range. For example, an observational study during 1997-2014 3 that compared nearly 34,000 patients taking only LT4 with those using LT4+LT3 (n = 327) or LT3 alone (n = 73) during a mean follow-up of 9.3 years (SD 5.6) and a maximum follow-up of 17.3 years. The study did not reveal higher mortality or morbidity risk due to cardiovascular disease, atrial fibrillation, or fractures. In addition, an analysis of 20 clinical trials that included almost 1,000 patients observed for up to 1 year indicated that peaks of serum T3 observed after the LT3 tablets only minimally affected serum TSH, heart rate, and blood pressure; the frequency of adverse reactions was similar to patients taking LT44 . Bone turnover markers were studied in two trials, and they remained within normal range. This was confirmed in a recent meta-analysis by Millan-Alanis et al 5 in which 18 clinical trials comparing LT4 vs LT4+LT3 therapy were evaluated found no differences in adverse events. In fact, we are unaware that combination therapy containing LT3 has ever been associated with increased occurrence of adverse reactions in patients maintaining normal TSH levels. (Hmm, my interjection).
2. In reference to a potential placebo effect associated with “entering a trial”, we found that 20 patients comprised the subgroup with the worst outcomes while on LT4 therapy and these patients were randomly distributed across the 3 treatment arms. 7 patients received LT4 on Arm-1 and 9 patients received LT4 on Arm-2. Thus, it is unlikely that a placebo effect played a role.
3. Baseline values were considered in the analyses. As stated under methods, differences between treatments were evaluated using mixed effects models. The primary outcome model included a fixed effect for treatment and a random effect of subject. Models were run with and without the inclusion of baseline scores to isolate between treatment differences. In the sub-analysis we also considered the baseline values but were not able to detect differences between baseline and LT4-treated arm.
4. In reference to a subgroup analysis of patients on DTE or LT4+LT3 prior to the trial, we found that there were 8 patients on DTE and 3 patients on LT4/LT3 at baseline. At the end of the study, out of these 11 patients, 6 preferred DTE and 5 preferred LT4/LT3 combination. This suggests that a placebo effect could not explain our findings. An appropriately powered study could address this point further. Of note, a preference for DTE had already been identified in our previous study6 . It has been our experience that most patients taking DTE show strong preference for continuing on DTE rather than switching to LT4.
Lyn Mynott - I found the url - tinyurl.com/2s3uhpey
Antonio Bianco's recommendation for T3 dosage
Letter from GP re T3 Hard Capsules
This is the information I have been using as a guide to my T3 treatment 
